160
Participants
Start Date
November 30, 2009
Primary Completion Date
February 29, 2012
Study Completion Date
December 31, 2012
EZN-2208
EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
Location#19, Troy
Location #23, Fairfax
Location #7, Norfolk
Location #21, Salem
Location #4, Raleigh
Location #8, Greenville
Location #36, New Port Richey
Location #1, Ocoee
Location #41, Columbus
Location #15, Carmel
Location #10, Minneapolis
Location #40, Niles
Location #14, Kansas City
Location #16, Columbia
Location #38, Lewisville
Location #13, Dallas
Location #30, Dallas
Location #17, Dallas
Location# 20, Tyler
Location #34, Arlington
Location #3, Bedford
Location #24, Fort Worth
Location #11, Houston
Location #35, Sugar Land
Location #31, McAllen
Location #9, Austin
Location #33, Abilene
Location # 28, Midland
Location #18, Denver
Location #5, Tucson
Location #12, Sedona
Location #2, Henderson
Location #32, Murrieta
Location #39, Oxnard
Location #27, Portland
Location #26, Dallas
Lead Sponsor
Enzon Pharmaceuticals, Inc.
INDUSTRY